CD79A Chimeric Antigen Receptors for Targeted, Persistent Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B cell malignancies, including chemotherapy, radiotherapy, and immunotherapy with antibodies like anti-CD19, anti-CD20, and CARs, have limited efficacy due to toxic side effects, poor pharmacokinetic profiles, and unpredictable antigen binding, leading to cytokine storms or insufficient cancer cell clearance.
Innovation Solution
Development of genetically modified immune effector cells expressing chimeric antigen receptors (CARs) with specific binding domains for CD79A, including extracellular, transmembrane, and intracellular signaling components, optimized for robust in vivo expansion and targeted cytotoxicity against CD79A-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy and radiotherapy are used to treat B cell malignancies, then cancer cells can be killed, but toxic side effects occur and therapeutic efficacy is limited
Solution Approach 1:
The patent uses genetically modified immune effector cells (such as CAR T-cells) as intermediaries to deliver targeted therapy. These cells express chimeric antigen receptors that specifically recognize B cell malignancy markers (CD19, CD20, CD22, CD79a), enabling selective killing of cancer cells while sparing healthy tissues, thus resolving the contradiction between therapeutic efficacy and toxic side effects
Solution Approach 2:
The patent replaces non-specific chemical warfare (chemotherapy) and energy-based destruction (radiotherapy) with a biological recognition system. The chimeric antigen receptors on immune effector cells provide specific molecular recognition of cancer cells through antigen-binding domains, substituting blind chemical attacks with targeted biological mechanisms, thereby improving efficacy while reducing toxicity
2Reliability
If immunotherapy with therapeutic antibodies (anti-CD19, anti-CD20, etc.) is used, then some cancer cells are targeted, but pharmacokinetic profiles are poor and antibodies are rapidly eliminated
Solution Approach 1:
The patent employs immune effector cells that are genetically modified to autonomously express chimeric antigen receptors. These cells can self-replicate, self-sustain, and persist in the patient's body for extended periods, continuously providing anti-cancer activity without requiring repeated antibody administrations, thus resolving the pharmacokinetic limitations of therapeutic antibodies
Solution Approach 2:
The patent performs preliminary genetic modification of immune effector cells ex vivo to equip them with chimeric antigen receptors before reinfusion. This preliminary action ensures the cells are pre-loaded with the necessary targeting machinery, enabling them to immediately and persistently recognize and eliminate cancer cells upon reinfusion, overcoming the short half-life of therapeutic antibodies
3Measurement precision
If CAR T cells with strong antigen binding are used, then cancer cell recognition is improved, but massive cytokine release occurs causing fatal immune reactions
Solution Approach 1:
The patent systematically varies parameters of the chimeric antigen receptors, including the antigen-binding domain (derived from different monoclonal antibodies with varying affinities), the hinge region length and composition, and the intracellular signaling domains. By optimizing these parameters, the patent achieves receptors with appropriate binding strength that effectively recognize cancer cells while modulating the activation threshold to prevent excessive cytokine release, thus resolving the contradiction between binding specificity and cytokine storm risk
4Object-generated harmful factors
If CAR T cells with weak antigen binding are used, then cytokine storm is avoided, but therapeutic efficacy in clearing cancer cells is insufficient
Solution Approach 1:
The patent creates composite chimeric antigen receptors that combine different functional elements: antigen-binding domains from therapeutic antibodies, engineered hinge regions for optimal spacing and orientation, and intracellular signaling domains (such as CD3ζ, 4-1BB, or CD28) that provide robust activation signals. This composite structure allows the receptor to achieve effective cancer cell killing at lower binding affinities by compensating with enhanced signaling efficiency, thus resolving the contradiction between avoiding cytokine storm and maintaining therapeutic efficacy
5Measurement precision
If therapeutic antibodies are used, then some target recognition is achieved, but penetration into tumor site and expression levels of target antigen are limited
Solution Approach 1:
The patent uses immune effector cells as living intermediaries that can actively navigate and penetrate into tumor sites. These cells express chimeric antigen receptors that recognize target antigens on cancer cells, and their cellular nature allows them to physically infiltrate tumor tissues more effectively than circulating antibodies, improving both target recognition and tumor site penetration simultaneously
Data Source
AI summary
The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.